India — July-September 2025 — The VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®), independently developed by MicroPort CardioFlow Medtech Corporation (CardioFlow, 02160.HK), has successfully completed its first 22 commercial implants in India, marking a significant advancement in accessible, innovative structural hearttherapies for local patients.

The milestone procedures were led by an expert team of physicians from premier institutions of India, including Christian Medical College (Vellore), Narayana Institute of Cardiac Sciences (Bangalore), PGIMER (Chandigarh), Medanta Group of Hospitals (Gurugram), Sir J J Group of Hospitals (Mumbai), Criticare Asia Medico Hospital (Mumbai), Max Hospital (Delhi), Kovai Medical Centre (Coimbatore), Sri Kauvery Medical Centre (Chennai), Magnum Heart Institute (Nashik), Apex Heart Institute (Ahmedabad).

With Lead Proctors Dr. Ole De Backer (Denmark), Dr. Amat Santos (Spain), Dr. J Kim (Korea), Dr. B H Hwang (Korea), Dr. Anuruck Jeamanukoolkit (Thailand) providing expert guidance, the cases demonstrated the system's exceptional clinical performance—including rapid postoperative recovery through minimally invasive approaches and successful management of complex anatomies—validating its precision and adaptability.

As the world's first electrically retrievable TAVI system approved for market launch, VitaFlow Liberty^® obtained EU CE MDR certification in 2024, making it the first China-developed TAVI system to achieve this milestone, and promptly initiated clinical applications across multiple European countries. Since May 2025, its commercialization process has accelerated significantly, marked by its successful entry into seven new country markets within just two months and rapid adoption in numerous key hospitals. To date, the VitaFlow^® series of TAVI products have been introduced into over 20 countries and regions worldwide, covering more than 800 core hospitals, and have treated over 10,000 patients with aortic valve disease.

The successful completion of the first commercial implants in India, the world's most populous country, not only exemplifies successful collaboration between top-tier heart centers in Europe and Asia and the sharing of medical technology within Asia, but also reflects the innovative integration of "Intelligently manufactured in China" products into international healthcare systems. Furthermore, this milestone will assist the company in further expanding into Asian and global markets, thereby continuously enhancing its profitability. It will also help promote high-quality, accessible advanced medical solutions for a greater number of patients, injecting innovative momentum into the global field of structural heart disease intervention.